Tags

Type your tag names separated by a space and hit enter

Current Status of Cell-Based Therapies for COVID-19: Evidence From Mesenchymal Stromal Cells in Sepsis and ARDS.
Front Immunol. 2021; 12:738697.FI

Abstract

The severe respiratory consequences of the coronavirus disease 2019 (COVID-19) pandemic have prompted the urgent need for novel therapies. Cell-based therapies, primarily using mesenchymal stromal cells (MSCs), have demonstrated safety and potential efficacy in the treatment of critical illness, particularly sepsis and acute respiratory distress syndrome (ARDS). However, there are limited preclinical data for MSCs in COVID-19. Recent studies have shown that MSCs could decrease inflammation, improve lung permeability, enhance microbe and alveolar fluid clearance, and promote lung epithelial and endothelial repair. In addition, MSC-based therapy has shown promising effects in preclinical studies and phase 1 clinical trials in sepsis and ARDS. Here, we review recent advances related to MSC-based therapy in the context of sepsis and ARDS and evaluate the potential value of MSCs as a therapeutic strategy for COVID-19.

Links

PMC Free PDF

Authors+Show Affiliations

Xu Z
State Key Laboratory of Respiratory Diseases, Department of Critical Care Medicine, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. Guangzhou Medical University, Guangzhou, China.
Huang Y
State Key Laboratory of Respiratory Diseases, Department of Critical Care Medicine, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. Guangzhou Medical University, Guangzhou, China.
Zhou J
School of Public Health, Southern Medical University, Guangzhou, China.
Deng X
State Key Laboratory of Respiratory Diseases, Department of Critical Care Medicine, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. Guangzhou Medical University, Guangzhou, China.
He W
State Key Laboratory of Respiratory Diseases, Department of Critical Care Medicine, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. Guangzhou Medical University, Guangzhou, China.
Liu X
State Key Laboratory of Respiratory Diseases, Department of Critical Care Medicine, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. Guangzhou Medical University, Guangzhou, China.
Li Y
State Key Laboratory of Respiratory Diseases, Department of Critical Care Medicine, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. Guangzhou Medical University, Guangzhou, China.
Zhong N
State Key Laboratory of Respiratory Diseases, Department of Critical Care Medicine, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. Guangzhou Medical University, Guangzhou, China.
Sang L
State Key Laboratory of Respiratory Diseases, Department of Critical Care Medicine, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. Guangzhou Medical University, Guangzhou, China. Guangzhou Laboratory, Guangzhou, China.

MeSH

COVID-19Cell- and Tissue-Based TherapyCytokine Release SyndromeHumansInflammationMesenchymal Stem Cell TransplantationMesenchymal Stem CellsSARS-CoV-2Sepsis

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

34659231

Citation

Xu, Zhiheng, et al. "Current Status of Cell-Based Therapies for COVID-19: Evidence From Mesenchymal Stromal Cells in Sepsis and ARDS." Frontiers in Immunology, vol. 12, 2021, p. 738697.
Xu Z, Huang Y, Zhou J, et al. Current Status of Cell-Based Therapies for COVID-19: Evidence From Mesenchymal Stromal Cells in Sepsis and ARDS. Front Immunol. 2021;12:738697.
Xu, Z., Huang, Y., Zhou, J., Deng, X., He, W., Liu, X., Li, Y., Zhong, N., & Sang, L. (2021). Current Status of Cell-Based Therapies for COVID-19: Evidence From Mesenchymal Stromal Cells in Sepsis and ARDS. Frontiers in Immunology, 12, 738697. https://doi.org/10.3389/fimmu.2021.738697
Xu Z, et al. Current Status of Cell-Based Therapies for COVID-19: Evidence From Mesenchymal Stromal Cells in Sepsis and ARDS. Front Immunol. 2021;12:738697. PubMed PMID: 34659231.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current Status of Cell-Based Therapies for COVID-19: Evidence From Mesenchymal Stromal Cells in Sepsis and ARDS. AU - Xu,Zhiheng, AU - Huang,Yongbo, AU - Zhou,Jianmeng, AU - Deng,Xiumei, AU - He,Weiqun, AU - Liu,Xiaoqing, AU - Li,Yimin, AU - Zhong,Nanshan, AU - Sang,Ling, Y1 - 2021/10/01/ PY - 2021/07/09/received PY - 2021/09/13/accepted PY - 2021/10/18/entrez PY - 2021/10/19/pubmed PY - 2021/11/4/medline KW - ARDS KW - COVID-19 KW - MSCs therapies KW - SARS-CoV-2 KW - sepsis SP - 738697 EP - 738697 JF - Frontiers in immunology JO - Front Immunol VL - 12 N2 - The severe respiratory consequences of the coronavirus disease 2019 (COVID-19) pandemic have prompted the urgent need for novel therapies. Cell-based therapies, primarily using mesenchymal stromal cells (MSCs), have demonstrated safety and potential efficacy in the treatment of critical illness, particularly sepsis and acute respiratory distress syndrome (ARDS). However, there are limited preclinical data for MSCs in COVID-19. Recent studies have shown that MSCs could decrease inflammation, improve lung permeability, enhance microbe and alveolar fluid clearance, and promote lung epithelial and endothelial repair. In addition, MSC-based therapy has shown promising effects in preclinical studies and phase 1 clinical trials in sepsis and ARDS. Here, we review recent advances related to MSC-based therapy in the context of sepsis and ARDS and evaluate the potential value of MSCs as a therapeutic strategy for COVID-19. SN - 1664-3224 UR - https://www.unboundmedicine.com/medline/citation/34659231/Current_Status_of_Cell_Based_Therapies_for_COVID_19:_Evidence_From_Mesenchymal_Stromal_Cells_in_Sepsis_and_ARDS_ DB - PRIME DP - Unbound Medicine ER -